Berenberg Bank analyst Gal Munda reiterated a Buy rating on AbCellera Biologics (ABCL) today and set a price target of $53.00. The company’s shares closed last Monday at $23.29, close to its 52-week low of $23.20.
According to TipRanks.com, Munda is ranked #915 out of 7406 analysts.
AbCellera Biologics has an analyst consensus of Strong Buy, with a price target consensus of $55.80.
See today’s analyst top recommended stocks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AbCellera Biologics Inc is a biotechnology company. The company develops antibodies to treat highly infectious diseases and various other types of diseases.
